New eye injection PRO-169 enters safety trial for Diabetes-Related vision loss

NCT ID NCT07429474

Not yet recruiting Disease control Sponsor: Laboratorios Sophia S.A de C.V. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial will test the safety of PRO-169, a form of bevacizumab injected into the eye, in 60 adults with diabetic macular edema. The study checks for immune reactions and side effects. It is not yet recruiting and focuses on safety, not whether it improves vision.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (PRO-169)
What this could lead to: If successful, this could show that PRO-169 is safe and may lead to a new treatment option for diabetic macular edema.
What could go wrong: This is an early Phase 1 trial with only 60 participants, so results may not apply broadly. The main focus is safety, not effectiveness, and there is a risk of immune reactions or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-DRUG ANTIBODIES (ADAS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-DRUG ANTIBODIES (ADAS) IMMUNOGENICITY

Contacts and locations

Locations

Asociación para Evitar la Ceguera en México I.A.P

Coyoacán, Mexico City, 04030, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.